Skip to main content
Top
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

A novel variable exonic region and differential expression of LINC00663 non-coding RNA in various cancer cell lines and normal human tissue samples

Authors: Esra Bozgeyik, Yusuf Ziya Igci, Mevan F. Sami Jacksi, Kaifee Arman, Serdar A. Gurses, Ibrahim Bozgeyik, Elif Pala, Onder Yumrutas, Ebru Temiz, Mehri Igci

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) are found to play crucial roles in several biological processes and have been associated with many complex human diseases including cancers. Several lines of evidences indicate that lncRNAs deregulated in many cancer tissues. In this particular study, differential expression of long intergenic non-coding RNA 663 (LINC00663) was demonstrated in various cancer cell lines and healthy human tissues by using RT-PCR and qPCR methods. While expression level of LINC00663 was most prominent in thyroid gland and uterus, it is least expressed in skeletal muscle tissues. Moreover, LINC00663 was found to be differentially expressed in various cancer cells. Particularly, its expression was highly diminished in DU-145, PC3, HGC-27, CRL-1469, A549, MCF7, and BCPAP cancer cells. Also, LINC00663 expression was most prominent in A172 glioblastoma cells. Additionally, a novel splice variant of LINC00663 RNA was also detected. The sequence and Basic Local Alignment Search Tool (BLAST) analysis results revealed the presence of a novel exonic region between exons 2 and 3. Subsequently, five potential splice variants showing high level of variation have been identified. Secondary structures of these variants with minimum free energy were also demonstrated. Furthermore, putative microRNA (miRNA) binding sites to these variants have been shown. In conclusion, LINC00663 was shown to be differentially expressed in various human tissues and cancer cell lines. Also, LINC00663 undergoes alternative splicing and the novel exonic region alters its secondary structure and its interactions with potential targeting miRNAs. The role of LINC00663 in cancer formation further needs to be investigated with a wide range of studies.
Literature
3.
go back to reference Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.CrossRefPubMed Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.CrossRefPubMed
4.
go back to reference Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed
6.
go back to reference Kara M, Yumrutas O, Ozcan O, Celik OI, Bozgeyik E, Bozgeyik I, et al. Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 2015. Kara M, Yumrutas O, Ozcan O, Celik OI, Bozgeyik E, Bozgeyik I, et al. Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 2015.
9.
go back to reference Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.CrossRefPubMed Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.CrossRefPubMed
10.
go back to reference Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long non coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5. Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long non coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5.
11.
go back to reference Bhan A, Mandal SS. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. Biochimica et Biophysica Acta (BBA)-Rev Cancer. 2015;1856:151–64.CrossRef Bhan A, Mandal SS. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. Biochimica et Biophysica Acta (BBA)-Rev Cancer. 2015;1856:151–64.CrossRef
13.
go back to reference Igci YZ, Arslan A, Akarsu E, Erkilic S, Igci M, Oztuzcu S, et al. Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma. Endocr Pathol. 2011;22:86–96.CrossRefPubMed Igci YZ, Arslan A, Akarsu E, Erkilic S, Igci M, Oztuzcu S, et al. Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma. Endocr Pathol. 2011;22:86–96.CrossRefPubMed
15.
go back to reference Kozomara A, Griffiths-Jones S. Mirbase: Integrating microRNA annotation and deep-sequencing data. Nucleic acids research 2010:gkq1027. Kozomara A, Griffiths-Jones S. Mirbase: Integrating microRNA annotation and deep-sequencing data. Nucleic acids research 2010:gkq1027.
16.
go back to reference Kozomara A, Griffiths-Jones S. Mirbase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2015:gkt1181. Kozomara A, Griffiths-Jones S. Mirbase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2015:gkt1181.
17.
go back to reference Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat-containing RNA and RNA surveillance factors at mammalian chromosome ends. Science. 2007;318:798–801.CrossRefPubMed Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat-containing RNA and RNA surveillance factors at mammalian chromosome ends. Science. 2007;318:798–801.CrossRefPubMed
18.
go back to reference de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. Dd3pca3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.PubMed de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. Dd3pca3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.PubMed
19.
go back to reference Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, et al. Dd3 pca3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–16.CrossRefPubMed Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, et al. Dd3 pca3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–16.CrossRefPubMed
20.
go back to reference Tsang FHC, Au SLK, Wei L, Fan DNY, Lee JMF, Wong CCL, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive mir-125b. Liver Int. 2015;35:1597–606.CrossRefPubMed Tsang FHC, Au SLK, Wei L, Fan DNY, Lee JMF, Wong CCL, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive mir-125b. Liver Int. 2015;35:1597–606.CrossRefPubMed
21.
go back to reference Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, et al. Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One. 2014;9, e104044.CrossRefPubMedPubMedCentral Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, et al. Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One. 2014;9, e104044.CrossRefPubMedPubMedCentral
22.
go back to reference Bovolenta M, Erriquez D, Valli E, Brioschi S, Scotton C, Neri M, et al. The DMD locus harbours multiple long non-coding RNAs which orchestrate and control transcription of muscle dystrophin mRNA isoforms. PLoS One. 2012;7, e45328.CrossRefPubMedPubMedCentral Bovolenta M, Erriquez D, Valli E, Brioschi S, Scotton C, Neri M, et al. The DMD locus harbours multiple long non-coding RNAs which orchestrate and control transcription of muscle dystrophin mRNA isoforms. PLoS One. 2012;7, e45328.CrossRefPubMedPubMedCentral
23.
go back to reference Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–5.CrossRefPubMed Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–5.CrossRefPubMed
25.
go back to reference Li J-H, Liu S, Zhou H, Qu L-H, Yang J-H. Starbase v2. 0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale clip-seq data. Nucleic acids research 2013:gkt1248. Li J-H, Liu S, Zhou H, Qu L-H, Yang J-H. Starbase v2. 0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale clip-seq data. Nucleic acids research 2013:gkt1248.
26.
go back to reference Wu T, Wang J, Liu C, Zhang Y, Shi B, Zhu X, et al. Npinter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res. 2006;34:D150–2.CrossRefPubMed Wu T, Wang J, Liu C, Zhang Y, Shi B, Zhu X, et al. Npinter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res. 2006;34:D150–2.CrossRefPubMed
27.
Metadata
Title
A novel variable exonic region and differential expression of LINC00663 non-coding RNA in various cancer cell lines and normal human tissue samples
Authors
Esra Bozgeyik
Yusuf Ziya Igci
Mevan F. Sami Jacksi
Kaifee Arman
Serdar A. Gurses
Ibrahim Bozgeyik
Elif Pala
Onder Yumrutas
Ebru Temiz
Mehri Igci
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4782-3

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine